Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma

Oncology
Mohamed HebbarFrançois-René Pruvot

Abstract

We assessed the safety and efficacy of docetaxel, a microtubule inhibitor, in patients with advanced hepatocellular carcinoma (HCC). HCC patients that were not suitable for local therapy, but who possessed measurable disease, good performance status and adequate organ function were eligible. Docetaxel was administered every 3 weeks at a dose of 100 mg/m(2) (or 75 mg/m(2) if transaminase levels were between 1.5 and 3.5 times the upper normal limit). Efficacy was assessed radiologically every three cycles of chemotherapy. Fifteen patients were enrolled: 11 males and 4 females; their median age was 64 years (range, 42-72 years). Nine patients had underlying cirrhosis. Four patients had been surgically treated before relapse (liver resection in 3 cases and transplantation in 1), 3 had been treated with arterial chemoembolization and 1 with arterial chemotherapy (doxorubicin). A total of 57 cycles of docetaxel were delivered (median 3, range 1-6). Significant toxicity was observed: mostly grade 3-4 neutropenia and fatigue (6 and 4 patients, respectively). Treatment had to be stopped because of toxicity in 6 patients, all having underlying cirrhosis. An important partial response was obtained in 1 patient, a result that enabled liver...Continue Reading

References

Jan 1, 1997·Investigational New Drugs·J G WallJ S Macdonald
Jun 13, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M G DonelliA Crosignani
Mar 27, 1999·Clinical Pharmacokinetics·S J Clarke, L P Rivory
Jul 25, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R E ColemanD W Miles
Feb 24, 2001·Clinics in Liver Disease·H B el-Serag
Apr 8, 2003·World Journal of Gastroenterology : WJG·Chang-Xin GengJi-Yao Wang
May 8, 2004·The Cancer Journal·Mike Cusnir, Yehuda Z Patt
Jun 16, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anna K NowakMichael Findlay
Apr 15, 2005·Journal of Gastroenterology·Josep M Llovet

❮ Previous
Next ❯

Citations

Nov 19, 2011·International Journal of Clinical Oncology·Ryoichi YanoMikio Masada
Oct 14, 2011·Future Oncology·Qian ZhouWinnie Yeo
Oct 27, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Koushiro OhtsuboNorio Sawabu
Jul 12, 2007·Cancer·Melanie B ThomasJames L Abbruzzese
Jan 15, 2010·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yutaka YataToshiro Sugiyama
Nov 12, 2013·Journal of the Egyptian National Cancer Institute·Omar Abdel-Rahman
Dec 3, 2020·Molecular Pharmaceutics·Rostislav A PetrovAlexander G Majouga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.